Literature DB >> 2046825

Exercise tolerance of end-stage renal disease patients.

M Sagiv1, J Rudoy, A Rotstein, N Fisher, J Ben-Ari.   

Abstract

The purpose of this study was to evaluate the exercise tolerance of end-stage renal disease patients, and to examine pulmonary function and blood lactate as its possible limiting factors. Ten end-stage renal disease patients (age 30 +/- 11) were tested at rest and in a subsequent graded treadmill test to exhaustion. Velocity was 4.8 km/h and the grade was incremented by 2.5% every 4 min. One minute of rest, used for blood sampling, separated successive stages. Pulmonary functions (FVC, FEV1) at rest were both 76% of predicted. Resting heart rate, systolic and diastolic blood pressures, and ventilatory equivalent values were higher than normal. At peak exercise, heart rate, oxygen uptake, oxygen pulse and blood lactic acid were lower than normally predicted for maximal exercise, while ventilatory equivalent and diastolic blood pressure were higher. Only six patients reached blood lactate levels beyond 4 mM.l-1 (onset of blood lactic acid), at which point they utilized 88 +/- 5% of their respective peak Vo2. The results suggest that the low exercise tolerance demonstrated in end-stage renal disease patients is not limited by the somewhat compromised pulmonary capacity or by excessive blood lactate levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046825     DOI: 10.1159/000186307

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Association of serum bicarbonate levels with gait speed and quadriceps strength in older adults.

Authors:  Matthew K Abramowitz; Thomas H Hostetter; Michal L Melamed
Journal:  Am J Kidney Dis       Date:  2011-02-26       Impact factor: 8.860

2.  Functional sympatholysis is impaired in end-stage renal disease.

Authors:  Justin D Sprick; Ryan M Downey; Doree Lynn Morison; Ida T Fonkoue; Yunxiao Li; Dana DaCosta; Derick Rapista; Jeanie Park
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-02-06       Impact factor: 3.619

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.